Medgenics Inc - MDGN - reported that it has received notice of ‘Intention to Grant’ from the European Patent Office for the patent application entitled “USE OF DERMAL MICRO ORGANS,” with allowed claims covering a core element of its Biopump protein therapy technology. This follows Similar U.S. Patent for Biopump Protein Therapy Technology and Expands Medgenics’ Intellectual Property Portfolio. Medgenics is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.
